<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511146</url>
  </required_header>
  <id_info>
    <org_study_id>AA-1023</org_study_id>
    <nct_id>NCT01511146</nct_id>
  </id_info>
  <brief_title>Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor</brief_title>
  <official_title>Intrahepatic and Systemic Chemotherapy Together With Antibody to Patients With Non-resectable Liver Metastases From Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Copenhagen University Hospital at Herlev</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if treatment with intrahepatic chemotherapy is a good
      options in patients with liver metastases. If the patients have colorectal cancer and never
      had got chemotherapy the investigators will use oxaliplatin together with capecitabine. If
      the patient is K-RAS wild type the investigators will add cetuximab. In patients who had
      received oxaliplatin or in patients with other cancers the investigators will use mitomycin
      and gemcitabine together with capecitabine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two regiment are used: N.B. The two regiments will be reported separately

        1. Mitomycin + Gemcitabine intrahepatic together with Capecitabine. This treatment can be
           offered patients with solid tumors where all standard treatments have been used. The
           patients are not allowed to have extrahepatic disease. The purpose of the treatment are
           to prolonged life.

        2. FOLFOX where oxaliplatin is given intrahepatic each second time. The treatment are only
           for patients with colorectal cancer where cure is possible but resection straight ahead
           is not possible. The patients are allowed to have their colorectal cancer in situ for
           operation latter on. If the patients are KRAS Wild-type, cetuximab are added.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor response according to RECIST 1.1. Number of patients with CR, PR, SD and PR will be recorded.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival, adverse events</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Metastasis</condition>
  <arm_group>
    <arm_group_label>Mitomycin+Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrahepatic treatment, where all standard treatments have been used</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>oxaliplatin 85 mg/m2 in 10 minutes</description>
    <arm_group_label>Mitomycin+Gemcitabine</arm_group_label>
    <other_name>Mitomycin c</other_name>
    <other_name>Gemcitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin + Gemcitabine</intervention_name>
    <description>Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2</description>
    <arm_group_label>Mitomycin+Gemcitabine</arm_group_label>
    <other_name>Mitomycin c</other_name>
    <other_name>Gemcitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  liver metastasis

          -  solid tumor

        Exclusion Criteria:

          -  poor performance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Finn O Larsen, M.D. , Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unaffliated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ole Larsen, ph.d., MD</last_name>
      <phone>+4538682329</phone>
      <email>olelar02@heh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Ole Larsen, ph.d., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2012</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oxaliplatin</keyword>
  <keyword>mitomycin</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>intrahepatic</keyword>
  <keyword>liver metastasis</keyword>
  <keyword>response in liver metastasis</keyword>
  <keyword>downsized to operation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

